Kamada (KMDA) AI Stock Analysis

• Market Cap: $1.46B
• Dividend Yield: N/A
• Average Volume (3M): 35.48K
• Price to Earnings (P/E): 24.7
• Beta (1Y): 0.71
• Revenue Growth: 10.86%
• EPS Growth: 14.94%
• Country: IL
• Employees: 420
• Sector: Healthcare
• Sector Strength: 37
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 25.04
• Shares Outstanding: 57,505,030
• 10 Day Avg. Volume: 38,552
• 30 Day Avg. Volume: 35,482
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.80
• Enterprise Value/Revenue: 6.99
• Enterprise Value/Gross Profit: 15.80
• Enterprise Value/Ebitda: 35.01
• 1Y Price Target: $4,453.43
• Price Target Upside: 79.57% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 66 Neutral
• Price Target: 2,646.00 ▲(6.69% Upside)

Kamada's overall stock score is bolstered by strong financial performance and a positive earnings call, indicating solid operational efficiency and growth potential. However, weak technical indicators suggest bearish market conditions, and the valuation is only moderately attractive. The absence of a dividend yield further limits its appeal to certain investors.

Positive Factors

Financial Performance

Kamada reported in-line financial results for their 1Q25, including revenues of $44.0 million, or 17% above those of 1Q24, and net income of $0.07 per share as compared to $0.04 per share in the prior year.

Product Portfolio

Strengthening the biosimilar portfolio is expected to yield significant revenue over the next five years, further diversifying its commercial offerings.

Strategic Expansion

Kamada continues the growth trajectory fueled by ex US expansion and increased demand.

Negative Factors

Risk Management

The stock may rally if the inhaled AAT program is discontinued, as some shareholders view it as a distraction from the company’s core competencies.

Kamada Business Overview & Revenue Model

Company Description

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

How the Company Makes Money

Kamada makes money primarily through the sales of its biopharmaceutical products. Its revenue model is centered around the commercialization of its proprietary plasma-derived therapeutics, both directly and through strategic distribution partnerships. Key revenue streams include product sales to hospitals, healthcare providers, and distributors. Additionally, Kamada engages in contract manufacturing for third parties, leveraging its expertise in plasma-derived therapeutics. The company also forms strategic partnerships and collaborations to co-develop and market its products in various regions, contributing to its earnings by expanding its market reach and maximizing product distribution.

Kamada Financial Statement Overview

Summary

Kamada demonstrates strong revenue growth and efficient cost management with a healthy equity position and robust cash generation. However, there is room for improvement in enhancing return on equity and overall profitability.

Income Statement

Kamada has demonstrated strong revenue growth over recent years, with a notable increase from $129.34M in 2022 to $167.24M in TTM. Gross Profit Margin has been healthy, currently at 44.2%, and Net Profit Margin is a solid 9.6%. The firm has improved its EBIT and EBITDA margins over time, indicating sound operational efficiency.

Balance Sheet

The company maintains a strong equity position with an Equity Ratio of 67.2%. The Debt-to-Equity Ratio is low at 0.044, indicating minimal leverage. However, Return on Equity is modest at 6.37%, suggesting potential for enhanced profitability.

Cash Flow

Kamada's Free Cash Flow has been stable, with a strong growth rate of 138.1% from 2023 to TTM. The Operating Cash Flow to Net Income Ratio is robust at 2.87, reflecting efficient cash generation relative to net income. The Free Cash Flow to Net Income Ratio is also strong at 2.27.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	160.95M	142.52M	129.34M	103.64M	133.25M
Gross Profit	69.97M	55.49M	46.70M	30.33M	47.55M
EBITDA	27.80M	21.53M	15.66M	5.21M	24.13M
Net Income	14.46M	8.28M	-2.32M	-2.23M	17.14M
Balance Sheet
Total Assets	372.25M	354.91M	322.38M	318.67M	210.66M
Cash, Cash Equivalents and Short-Term Investments	78.44M	55.64M	34.26M	18.59M	109.27M
Total Debt	11.06M	8.82M	20.60M	24.35M	4.94M
Total Liabilities	112.79M	110.89M	146.36M	141.84M	32.03M
Stockholders Equity	259.46M	244.02M	176.02M	176.82M	178.64M
Cash Flow
Free Cash Flow	36.85M	-1.53M	24.80M	-12.55M	13.62M
Operating Cash Flow	47.59M	4.32M	28.59M	-8.82M	19.11M
Investing Cash Flow	-10.74M	-5.84M	-3.78M	-61.05M	-13.13M
Financing Cash Flow	-13.91M	22.68M	-9.34M	18.59M	23.36M

Kamada Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2480.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:KMDA, the sentiment is Neutral. The current price of 2480 is below the 20-day moving average (MA) of 2556.40, below the 50-day MA of 2528.82, and above the 200-day MA of 2397.58, indicating a neutral trend. The MACD of -30.07 indicates Positive momentum. The RSI at 44.47 is Neutral, neither overbought nor oversold. The STOCH value of 25.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IL:KMDA.

Kamada Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KMDA	66 Neutral	$1.46B	24.73	6.44%	―	10.86%	14.94%
Sector *	51 Neutral	$7.38B	-0.04	-62.85%	2.34%	15.18%	-2.87%
BRSYF	―	$227.28M	55.40	7.41%	―	―	―
TEVA	53 Neutral	64.17B	―		―	-0.54%	58.34%
ILX	―	675.20M	19.76		2.02%	―	―
DNA	―	137.94M	6.25		―	―	―
NVLG	66 Neutral	710.12M	24.87		5.59%	25.30%	―